Header Logo

Melody Cobleigh

Concepts (330)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
68
2022
408
7.800
Why?
Receptor, ErbB-2
19
2022
51
3.550
Why?
Trastuzumab
17
2021
26
2.170
Why?
Antineoplastic Agents
20
2019
197
2.160
Why?
Antineoplastic Combined Chemotherapy Protocols
20
2022
244
1.490
Why?
Drug Resistance, Neoplasm
2
2020
69
1.260
Why?
Antibodies, Monoclonal
14
2011
176
1.170
Why?
Biomarkers, Tumor
9
2019
205
1.130
Why?
Neoplasm Metastasis
19
2019
107
0.970
Why?
Female
72
2022
15166
0.880
Why?
Antineoplastic Agents, Immunological
2
2020
15
0.840
Why?
Carcinoma, Intraductal, Noninfiltrating
2
2021
12
0.830
Why?
Mastectomy, Segmental
3
2021
29
0.770
Why?
STAT6 Transcription Factor
1
2020
11
0.690
Why?
Humans
78
2022
26946
0.660
Why?
Breast Neoplasms, Male
1
2019
11
0.660
Why?
Antibodies, Monoclonal, Humanized
17
2014
85
0.650
Why?
Class Ia Phosphatidylinositol 3-Kinase
1
2019
4
0.650
Why?
Protein Kinase Inhibitors
2
2019
53
0.640
Why?
Middle Aged
44
2021
8887
0.640
Why?
MAP Kinase Signaling System
1
2019
36
0.630
Why?
Central Nervous System Neoplasms
1
2018
11
0.620
Why?
Tamoxifen
7
2012
30
0.560
Why?
Aromatase Inhibitors
4
2012
8
0.560
Why?
ErbB Receptors
3
2008
54
0.540
Why?
Antineoplastic Agents, Hormonal
3
2012
18
0.480
Why?
Adult
37
2020
7793
0.470
Why?
Aged
34
2020
8979
0.440
Why?
Molecular Targeted Therapy
2
2016
33
0.440
Why?
Receptors, Progesterone
7
2019
26
0.440
Why?
Carcinoma
2
2011
67
0.420
Why?
Estrogen Replacement Therapy
3
1999
19
0.420
Why?
Aged, 80 and over
18
2020
4771
0.410
Why?
Enzyme Inhibitors
4
2006
114
0.400
Why?
Chemotherapy, Adjuvant
10
2016
81
0.380
Why?
Angiogenesis Inhibitors
3
2014
15
0.350
Why?
Cell Proliferation
3
2020
174
0.340
Why?
Hypertension
3
2014
191
0.310
Why?
Cell Line, Tumor
2
2020
255
0.310
Why?
Receptors, Estrogen
8
2013
65
0.310
Why?
Neoplasm Staging
11
2019
362
0.300
Why?
Treatment Outcome
14
2021
3454
0.300
Why?
Prospective Studies
5
2021
1771
0.300
Why?
Menopause
2
2000
101
0.290
Why?
Ventricular Dysfunction, Left
2
2019
34
0.290
Why?
Prognosis
7
2018
781
0.280
Why?
Neoplasm Recurrence, Local
6
2019
205
0.260
Why?
Genes, BRCA2
3
2020
10
0.250
Why?
Genes, BRCA1
3
2020
12
0.250
Why?
Disease-Free Survival
6
2017
174
0.240
Why?
Ovarian Neoplasms
3
2019
72
0.230
Why?
Registries
3
2021
188
0.230
Why?
Survival Analysis
7
2018
256
0.230
Why?
Survival Rate
5
2019
340
0.220
Why?
Angina Pectoris
1
2004
16
0.220
Why?
Postmenopause
5
2010
54
0.220
Why?
Young Adult
2
2019
1984
0.210
Why?
Quinazolines
2
2016
16
0.200
Why?
Cancer Survivors
1
2022
12
0.200
Why?
Quality of Life
9
2007
627
0.200
Why?
Quinolines
2
2022
8
0.190
Why?
Follow-Up Studies
6
2019
1784
0.190
Why?
Combined Modality Therapy
5
2018
299
0.190
Why?
Bevacizumab
7
2014
21
0.180
Why?
Carcinoma, Squamous Cell
3
1987
171
0.180
Why?
Head and Neck Neoplasms
3
1987
148
0.180
Why?
Immunohistochemistry
5
2017
365
0.180
Why?
Vascular Endothelial Growth Factor A
2
2013
74
0.180
Why?
Disease Progression
7
2011
673
0.170
Why?
Germ-Line Mutation
1
2020
14
0.170
Why?
Epithelial-Mesenchymal Transition
1
2020
6
0.170
Why?
Menopause, Premature
2
2000
7
0.170
Why?
Stroke Volume
2
2019
54
0.170
Why?
Cell Survival
1
2020
120
0.170
Why?
Isoflavones
1
2000
2
0.170
Why?
Estrogen Receptor alpha
1
2019
16
0.170
Why?
Gene Expression Regulation, Neoplastic
1
2020
116
0.160
Why?
Cohort Studies
4
2019
1882
0.160
Why?
Gene Targeting
1
2019
10
0.160
Why?
Folic Acid Deficiency
1
2019
7
0.160
Why?
Phthalazines
1
2019
6
0.160
Why?
TOR Serine-Threonine Kinases
1
2019
13
0.160
Why?
S Phase
1
1999
11
0.160
Why?
Gene Knockdown Techniques
1
2019
45
0.160
Why?
Fenretinide
3
2010
5
0.160
Why?
Odds Ratio
2
2018
268
0.160
Why?
Proto-Oncogene Proteins c-akt
1
2019
57
0.150
Why?
Piperazines
1
2019
85
0.150
Why?
Chimerism
1
2018
4
0.150
Why?
BRCA1 Protein
1
2018
4
0.150
Why?
BRCA2 Protein
1
2018
4
0.150
Why?
Disease Management
1
2018
102
0.150
Why?
Mammography
3
2022
47
0.140
Why?
Circulating Tumor DNA
1
2017
6
0.140
Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
1
2017
11
0.140
Why?
Neoplasms, Multiple Primary
1
2017
39
0.140
Why?
Stomach Neoplasms
1
2017
34
0.140
Why?
Signal Transduction
1
2019
443
0.130
Why?
Paclitaxel
4
2013
49
0.130
Why?
Practice Guidelines as Topic
2
2012
261
0.130
Why?
Menstruation Disturbances
1
1996
1
0.130
Why?
Disease Models, Animal
1
2019
597
0.130
Why?
Survivors
4
2004
70
0.130
Why?
Cytostatic Agents
1
2016
2
0.130
Why?
Ovary
1
1996
23
0.130
Why?
Randomized Controlled Trials as Topic
7
2016
288
0.130
Why?
Phosphatidylinositol 3-Kinases
1
2016
44
0.130
Why?
Aspirin
1
2016
83
0.120
Why?
Male
7
2021
14718
0.120
Why?
Gene Amplification
2
2013
21
0.120
Why?
Maytansine
1
2014
2
0.110
Why?
Patient Reported Outcome Measures
1
2018
499
0.110
Why?
Membrane Glycoproteins
1
2014
68
0.110
Why?
Mammary Neoplasms, Experimental
1
1994
2
0.110
Why?
Genes, erbB-2
2
2005
7
0.110
Why?
Lymph Nodes
2
2005
72
0.110
Why?
Animals
2
2019
3627
0.110
Why?
Estrogens
3
2000
25
0.110
Why?
Nerve Tissue Proteins
1
2014
154
0.110
Why?
Mutation
4
2018
347
0.110
Why?
Neoplasms, Second Primary
3
2000
38
0.100
Why?
Deoxycytidine
3
2011
23
0.100
Why?
Gonadotropin-Releasing Hormone
1
2012
10
0.100
Why?
Ovariectomy
1
2012
26
0.100
Why?
Clinical Trials as Topic
4
2005
215
0.100
Why?
Polymorphism, Single Nucleotide
2
2014
278
0.100
Why?
Medication Adherence
1
2012
49
0.100
Why?
Adenocarcinoma
1
1993
137
0.100
Why?
Drugs, Investigational
1
2011
5
0.090
Why?
Safety
5
2004
37
0.090
Why?
Lymphatic Metastasis
3
2005
92
0.090
Why?
Retrospective Studies
7
2022
3522
0.090
Why?
Drug Administration Schedule
4
2008
158
0.090
Why?
Diet
2
2002
219
0.080
Why?
Neoplasms, Hormone-Dependent
2
2000
2
0.080
Why?
Neoplastic Stem Cells
2
2000
6
0.080
Why?
Mastectomy
1
2009
36
0.080
Why?
Vascular Endothelial Growth Factor Receptor-2
1
2008
9
0.080
Why?
Ki-67 Antigen
2
2005
18
0.080
Why?
Severity of Illness Index
2
2005
877
0.080
Why?
Doxorubicin
2
2004
57
0.070
Why?
Protein-Tyrosine Kinases
1
2008
15
0.070
Why?
Indoles
1
2008
32
0.070
Why?
Pyrroles
1
2008
23
0.070
Why?
Antineoplastic Agents, Phytogenic
1
2007
9
0.070
Why?
Contraindications
3
1998
31
0.070
Why?
Longevity
2
2000
31
0.070
Why?
Etoposide
1
1987
27
0.070
Why?
Matrix Metalloproteinase Inhibitors
2
2004
6
0.070
Why?
Breast Self-Examination
1
2007
3
0.070
Why?
Keratin-6
1
2006
2
0.070
Why?
Keratin-5
1
2006
2
0.070
Why?
Clinical Trials, Phase II as Topic
2
2003
20
0.070
Why?
Drug Interactions
2
1998
34
0.070
Why?
Proportional Hazards Models
3
2016
346
0.060
Why?
Family
1
2007
103
0.060
Why?
Multivariate Analysis
3
2004
326
0.060
Why?
Logistic Models
3
2005
395
0.060
Why?
Patient Education as Topic
1
2007
130
0.060
Why?
Drug Evaluation
7
1989
20
0.060
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2005
137
0.060
Why?
Genetic Testing
1
2005
57
0.060
Why?
Mass Screening
2
2022
168
0.060
Why?
Cardiovascular Diseases
2
2000
321
0.060
Why?
Gene Expression Profiling
1
2005
138
0.060
Why?
Gene Expression
1
2005
199
0.060
Why?
Double-Blind Method
2
2010
404
0.060
Why?
Recurrence
1
2005
306
0.060
Why?
RNA, Messenger
1
2005
310
0.060
Why?
Capecitabine
3
2011
3
0.060
Why?
Organic Chemicals
1
2004
4
0.060
Why?
Fluorouracil
3
2011
46
0.060
Why?
Hematopoietic Stem Cell Transplantation
2
1995
109
0.050
Why?
Breast Density
1
2022
4
0.050
Why?
Pilot Projects
2
2020
417
0.050
Why?
Hydroxamic Acids
1
2002
4
0.050
Why?
Nitriles
1
2002
14
0.050
Why?
Societies, Medical
1
2003
121
0.050
Why?
Triazoles
1
2002
29
0.050
Why?
Biomarkers
2
2016
561
0.050
Why?
Heart Diseases
2
2001
62
0.050
Why?
Hospitalization
1
2004
301
0.050
Why?
Risk Factors
4
2005
2295
0.050
Why?
Vinblastine
1
1981
9
0.050
Why?
Early Detection of Cancer
1
2022
103
0.050
Why?
Feeding Behavior
1
2002
85
0.050
Why?
Checkpoint Kinase 2
1
2020
8
0.040
Why?
Genetic Predisposition to Disease
1
2022
381
0.040
Why?
Genes, p53
1
2020
18
0.040
Why?
Genotype
2
2014
346
0.040
Why?
Health Behavior
1
2002
159
0.040
Why?
Estrogens, Non-Steroidal
1
2000
1
0.040
Why?
Embryonal Carcinoma Stem Cells
1
2000
1
0.040
Why?
Phytoestrogens
1
2000
4
0.040
Why?
Selective Estrogen Receptor Modulators
1
2000
3
0.040
Why?
Gonadal Steroid Hormones
1
2000
10
0.040
Why?
Hot Flashes
1
2000
11
0.040
Why?
Plant Preparations
1
2000
7
0.040
Why?
Osteoporosis, Postmenopausal
1
2000
5
0.040
Why?
Antigens, CD
2
2017
50
0.040
Why?
In Situ Hybridization, Fluorescence
2
2013
36
0.040
Why?
Hormone Replacement Therapy
1
2000
35
0.040
Why?
Ventricular Function, Left
1
2019
38
0.040
Why?
Confidence Intervals
1
1999
92
0.040
Why?
Weight Gain
1
2000
64
0.040
Why?
Folic Acid
1
2019
21
0.040
Why?
Likelihood Functions
1
1999
27
0.040
Why?
Time Factors
2
2002
1429
0.040
Why?
Taxoids
2
2008
10
0.040
Why?
Anthracyclines
2
2008
17
0.040
Why?
Flushing
1
1998
3
0.040
Why?
Estrogen Antagonists
1
1998
3
0.040
Why?
Dyspareunia
1
1998
5
0.040
Why?
Vaginitis
1
1998
3
0.040
Why?
Primary Ovarian Insufficiency
1
1998
8
0.040
Why?
Endometrial Neoplasms
1
1998
13
0.040
Why?
Mood Disorders
1
1998
27
0.040
Why?
Magnetic Resonance Imaging
1
2022
1106
0.040
Why?
Mismatch Repair Endonuclease PMS2
1
2017
5
0.040
Why?
Pedigree
1
2017
65
0.040
Why?
Cadherins
1
2017
34
0.040
Why?
Lung Neoplasms
3
1989
551
0.030
Why?
Clinical Trials, Phase III as Topic
2
2011
14
0.030
Why?
Obesity
1
2000
310
0.030
Why?
Biopsy
1
2017
201
0.030
Why?
Osteoporosis
1
1998
77
0.030
Why?
Cardiotoxicity
1
2016
8
0.030
Why?
Drug Monitoring
1
2016
11
0.030
Why?
Sleep Wake Disorders
1
1998
123
0.030
Why?
Class I Phosphatidylinositol 3-Kinases
1
2016
9
0.030
Why?
Echocardiography
1
2016
73
0.030
Why?
Glycogen Synthase Kinase 3 beta
1
2016
13
0.030
Why?
MCF-7 Cells
1
2016
15
0.030
Why?
Proto-Oncogene Proteins p21(ras)
1
2016
20
0.030
Why?
Phosphorylation
1
2016
148
0.030
Why?
Adolescent
2
2019
2156
0.030
Why?
Biological Availability
1
2014
17
0.030
Why?
Tissue Distribution
1
2014
33
0.030
Why?
United States
2
2014
2034
0.030
Why?
Enzyme-Linked Immunosorbent Assay
1
2014
90
0.030
Why?
Neoplasms, Experimental
1
1994
9
0.030
Why?
Bone Marrow Transplantation
1
1994
21
0.030
Why?
Tumor Cells, Cultured
1
1994
129
0.030
Why?
Linear Models
1
2014
248
0.030
Why?
Incidence
1
1996
758
0.030
Why?
Genome-Wide Association Study
1
2014
279
0.030
Why?
Blood Pressure
1
2014
194
0.030
Why?
Tissue Array Analysis
1
2013
7
0.030
Why?
Vascular Endothelial Growth Factor C
1
2011
1
0.020
Why?
Neuropilin-1
1
2011
3
0.020
Why?
Neoplasms
1
1994
237
0.020
Why?
Night Blindness
1
2010
2
0.020
Why?
Cyclophosphamide
2
2004
48
0.020
Why?
Vidarabine Phosphate
1
1989
1
0.020
Why?
Arabinonucleotides
1
1989
1
0.020
Why?
Spiro Compounds
1
1989
1
0.020
Why?
Organometallic Compounds
1
1989
20
0.020
Why?
Antimetabolites, Antineoplastic
1
1989
17
0.020
Why?
Premenopause
1
2009
11
0.020
Why?
Neoplasms, Radiation-Induced
1
2009
12
0.020
Why?
Carcinoma, Renal Cell
1
1989
46
0.020
Why?
Radiotherapy Dosage
1
2009
99
0.020
Why?
Haplotypes
1
2008
58
0.020
Why?
Kidney Neoplasms
1
1989
78
0.020
Why?
Statistics, Nonparametric
1
2008
124
0.020
Why?
Erlotinib Hydrochloride
1
2008
11
0.020
Why?
Bridged-Ring Compounds
1
2008
1
0.020
Why?
Hematologic Diseases
1
2008
10
0.020
Why?
Skin Neoplasms
1
2009
80
0.020
Why?
Gastrointestinal Diseases
1
2008
30
0.020
Why?
Administration, Oral
1
2008
108
0.020
Why?
Alzheimer Disease
1
2000
2109
0.020
Why?
Fatigue
1
2008
57
0.020
Why?
Culture Media
1
1987
32
0.020
Why?
Cell Division
1
1987
86
0.020
Why?
Fibroblasts
1
1987
58
0.020
Why?
Statistics as Topic
1
1987
105
0.020
Why?
Cell Differentiation
1
1987
137
0.020
Why?
Cell Line
1
1987
273
0.020
Why?
Carcinoma, Non-Small-Cell Lung
1
1989
242
0.020
Why?
Carboplatin
1
2006
25
0.020
Why?
Thiadiazoles
1
1986
1
0.020
Why?
Poverty
1
2007
96
0.020
Why?
Illinois
1
2007
250
0.020
Why?
Cells, Cultured
1
1987
518
0.020
Why?
Probability
1
2005
87
0.020
Why?
Remission Induction
1
2005
90
0.020
Why?
Women's Health
1
2007
174
0.020
Why?
Models, Statistical
1
2005
127
0.010
Why?
Oncology Nursing
1
2004
2
0.010
Why?
Patient Selection
1
2005
192
0.010
Why?
Carcinoma, Bronchogenic
1
1983
6
0.010
Why?
Imidazoles
1
2004
59
0.010
Why?
Survival
1
2003
2
0.010
Why?
Organizational Policy
1
2003
15
0.010
Why?
Axilla
1
2002
13
0.010
Why?
Mesonephroma
1
1982
1
0.010
Why?
Maximum Tolerated Dose
1
2002
13
0.010
Why?
Expert Testimony
1
2002
12
0.010
Why?
Mediastinal Neoplasms
1
1982
11
0.010
Why?
In Situ Hybridization
1
2002
49
0.010
Why?
Tumor Suppressor Protein p53
1
2002
92
0.010
Why?
Vindesine
1
1981
2
0.010
Why?
Leukopenia
1
1981
7
0.010
Why?
Neuromuscular Diseases
1
1981
5
0.010
Why?
Evidence-Based Medicine
1
2002
161
0.010
Why?
Predictive Value of Tests
1
2002
474
0.010
Why?
Multicenter Studies as Topic
1
2001
43
0.010
Why?
Salvage Therapy
1
2001
35
0.010
Why?
Fever
1
2001
34
0.010
Why?
Neoplasm Proteins
1
2001
56
0.010
Why?
Age Factors
1
2002
759
0.010
Why?
Palliative Care
1
2001
110
0.010
Why?
Cross-Sectional Studies
1
2002
890
0.010
Why?
Pain
1
2001
406
0.010
Why?
Translations
1
1997
9
0.010
Why?
Self Concept
1
1997
37
0.010
Why?
Surveys and Questionnaires
1
2002
1140
0.010
Why?
Sensitivity and Specificity
1
1997
479
0.010
Why?
Reproducibility of Results
1
1997
673
0.010
Why?
Neoplasm Invasiveness
1
1994
93
0.010
Why?
Antigens, CD34
1
1994
12
0.010
Why?
Cell Separation
1
1994
24
0.010
Why?
Cisplatin
1
1994
58
0.010
Why?
Anthracenes
1
1983
6
0.000
Why?
Tomography
1
1982
12
0.000
Why?
Radiography, Thoracic
1
1982
27
0.000
Why?
Drug Therapy, Combination
1
1982
161
0.000
Why?
Mortality
1
1982
89
0.000
Why?
Ultrasonography
1
1982
227
0.000
Why?
Cobleigh's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (330)
Explore
_
Co-Authors (20)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_